GlobeNewswire Inc.··Perspective Therapeutics, Inc.Perspective Therapeutics Advances Three Pipeline Programs Ahead of 2026 ASCO Presentation
Perspective Therapeutics will present clinical data from all three radiopharmaceutical programs at 2026 ASCO, including melanoma trial results showing 29% response rate.
CATXclinical trialssolid tumors